financetom
Business
financetom
/
Business
/
Why Is Broadridge Financial Solutions Stock Trading Higher Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is Broadridge Financial Solutions Stock Trading Higher Today?
Aug 6, 2024 9:53 AM

Broadridge Financial Solutions Inc ( BR ) shares are trading higher after it reported fourth-quarter FY24 results.

The company reported revenue growth of 6% Y/Y to $1.94 billion, missing the consensus of $1.96 billion.

Recurring revenues increased 5% to $1.33 billion, and Distribution revenues rose 4% to $542 million. Event-driven segment revenues grew 29% Y/Y to $76 million in the quarter.

Adjusted operating income rose 5% Y/Y to $559 million, with margin contracted to 28.8% from 28.9% a year ago. Adjusted EPS of $3.50 (+9% Y/Y) in line with the consensus.

As of June-end, Broadridge held $304.4 million in cash and equivalents.

FY25 Outlook: Broadridge Financial Solutions ( BR ) expects recurring revenue constant currency growth of 5% – 7% Y/Y and adjusted EPS growth of 8% – 12% Y/Y, representing $8.35 – $8.66 versus the estimate of $8.47.

Tim Gokey, Broadridge CEO, said, “The combination of our strong fiscal year 2024 results and fiscal year 2025 guidance has Broadridge well on-track to deliver again on our three-year financial objectives.”

“We remain committed to a balanced approach to capital allocation. In fiscal year 2024, we repurchased $450 million of our shares and announced three tuck-in acquisitions. I am also pleased to report that our Board has approved a 10% increase in our annual dividend to $3.52, marking the 12th double-digit increase in the past thirteen years.”

Investors can gain exposure to the stock via Motley Fool Mid-Cap Growth ETF and Bahl & Gaynor Small/Mid Cap Income Growth ETF ( SMIG ) .

Price Action: BR shares are up 6.59% at $222.27 at the last check Tuesday.

Image via Pexels/ Karolina Kaboompics

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
US investor strikes $1 billion merger to create bitcoin treasury company
US investor strikes $1 billion merger to create bitcoin treasury company
Jun 24, 2025
(ProCap BTC corrects that Citadel is not an investor in the new company in paragraph 7; Corrects name of company to 'MicroStrategy ( MSTR )' (not 'Strategy') in paragraph 4) * ProCap BTC raises $750 million in equity and convertible note * ProCap Financial to use bitcoin for revenue via lending, derivatives * Institutional investors commit capital, but Reuters can't...
Baselode Energy Buying Forum Energy Metals; Combined Co Will Be Named Geiger Energy
Baselode Energy Buying Forum Energy Metals; Combined Co Will Be Named Geiger Energy
Jun 24, 2025
02:52 PM EDT, 06/24/2025 (MT Newswires) -- Baselode Energy ( BSENF ) on Tuesday entered into a definitive arrangement agreement that will see it buy all of the issued and outstanding common shares of Forum Energy Metals ( FDCFF ) as part of a refreshed strategy to pursue uranium discoveries within one of the world's most prospective and emerging uranium...
FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy
FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy
Jun 24, 2025
Capricor Therapeutics Inc ( CAPR ) on Tuesday provided regulatory updates related to its Biologics License Application (BLA) for Deramiocel, the company’s lead cell therapy candidate for the treatment of Duchenne Muscular Dystrophy (DMD)—associated cardiomyopathy. DMD is an X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved